DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for fleck corneal dystrophy — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleFleck corneal dystrophy maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for fleck corneal dystrophy is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
phosphoinositide kinase, FYVE-type zinc finger containing (PIKFYVE) — PIKFYVE is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet apo structuredrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 7K2V · 6.6 Å · ligand none (apo structure). Experimental structure, not a prediction.
What the evidence adds up to
A 2015 pilot study of two patients with Fuchs corneal endothelial dystrophy who underwent combined cataract surgery and central descemetorhexis without endothelial transplantation found that the procedure was not acceptable therapy. In both patients, residual disciform stromal edema corresponded to the diameter of the descemetorhexis and caused loss of visual acuity. Vision improved to 20/40 -1 in one case and to 150 -1 in the other over 10 to 12 months, but endothelial cell repopulation could not be confirmed due to persistent corneal edema. The authors concluded that the postoperative visual acuity was relatively poor and visual recovery slow.
A 1987 report describes a 17-year-old female patient with epithelial corneal dystrophy characterised by maps, dots and fingerprints in the central corneal epithelium of both eyes. The diagnosis was supported by slitlamp examination and a dominant family history. The condition is described as very rare, and the patient presented with ocular irritation from recurrent corneal erosion.
A 2010 review of the genetics of corneal dystrophies notes that genes have been identified for superficial dystrophies such as Meesmann (KRT3/KRT12), stromal dystrophies (BIGH3/TGFB1), and endothelial dystrophies (SLC4A11, COL8A2). The review states that understanding of less recognised phenotypes such as brittle cornea syndrome has shed light on corneal homeostasis and thickness regulation. The authors claim that gene identification improves diagnosis and understanding of disease mechanisms, and that this will lead to new therapies, but no specific treatment data are provided.
No abstract in this set reports a drug tested for fleck corneal dystrophy. The 2015 study explicitly advises against the surgical procedure it tested. What is missing for any potential therapy in fleck corneal dystrophy is a specific molecular target, a drug candidate, any preclinical or clinical trial data, and funding for such work. Patient stratification by genetic subtype has not been attempted for this condition.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Cornea · 2015 · 62 citations
Planned Descemetorhexis Without Endothelial Keratoplasty in Eyes With Fuchs Corneal Endothelial Dystrophy
AbstractPURPOSE: The purpose of this study was to describe the results of a simple 6-mm central descemetorhexis in eyes with Fuchs corneal endothelial dystrophy. METHODS: This prospective nonrandomized IRB approved pilot study was performed on 2 patients with coexisting Fuchs dystrophy and cataract who underwent combined phacoemulsification and descemetorhexis without endothelial transplantation. RESULTS: In each patient, residual disciform stromal edema corresponded to the diameter of the descemetorhexis and led to an associated loss of visual acuity. Vision improved to 20/40 -1 in case 1 and to 150 -1 in case 2 during a follow-up period of 12 and 10 months, respectively. Endothelial cell repopulation of the descemetorhexis could not be confirmed because of the presence of persistent corneal edema. CONCLUSIONS: Because of the relatively poor postoperative visual acuity and slow visual recovery, a simple descemetorhexis is not an acceptable form of therapy for eyes with Fuchs corneal endothelial dystrophy.
AbstractEpithelial corneal dystrophy is a very rare disease which is characterized by maps, dots and fingerprints changes involving the central corneal epithelium binocularly. A 17 year-old female patient came to our hospital with the chief complaint of ocular irritation due to recur-rent corneal erosion. Slitlamp biomicroscopic examination & dominant family history supported the diagnosis. Literatures concerning about corneal dystrophy & the pathological changes of corneal epithelial dystrophy were reviewed.
AbstractAbstract Purpose To provide an overview of progress in understanding of the genetics of corneal dystrophies. Methods A systematic review, including case presentations, to illustrate insights into genes underlying inherited corneal dystrophies: Results Recent advances have extended our undestanding of the causation of a range of classical inherited corneal dystrophies. This includes the identifcation of genes underlying superficial (e.g Meesmann, KRT3/KRT12), stromal (BIGH3/TGFB1) and endothelial (SLC4A11, COL8A2) dysrophies. Understanding of less well‐recognised phenotypes (e.g brittle cornea syndrome) has also shed light on the regulation of corneal homeostasis including the control of corneal thickness. Conclusion Identification of the genes underlying corneal inherited disease improves diagnosis of corneal dysrophies, sheds light on disease mechanisms and has potential to improve patient management. In the futuire this will lead to new therapeutic modalities for an important group of conditions associated with significant visual loss.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
